|
|
 |
|
Viewing report
|
|
|
|
Dr Reddy's Laboratories Generics Company Intelligence Report
Espicom Business Intelligence Ltd, Jan 2011, Pages: 16
Dr Reddy’s is the second largest pharmaceutical manufacturer in India, behind Ranbaxy. The company sells APIs, branded drugs and generics. Most of its branded drugs are copies of drugs patented in the West, but not in India.
For the fiscal year ended 31st March 2010, Dr Reddy's reported total revenues worth Rs70,277 million (US$1,483.5 million), representing a modest increase of 1.2% over
the prior year, when revenues reached Rs69,441 million. However, the firm announced profit after tax of Rs1,068 million (US$22.5 million), compared to a loss in the previous year of Rs5,168 million.
Dr Reddy’s is also represented in Western Europe, Russia and Asia. In 2002, the company made its first overseas acquisitions, both in the UK. In November 2005, Dr Reddy’s announced it had signed a definitive agreement to acquire Roche’s API business in Cuernavaca, Mexico. In March 2006, Dr Reddy’s completed its purchase of the German generic pharmaceutical firm, betapharm, from 3i, in a deal worth 480 million euros in cash. In 2007, the company announced that it was making the UK its European headquarters.
In August 2010, Dr Reddy's announced that it had launched Cresp, which it claimed was the first darbepoetin alpha copy in the world and the only one available in India. The product is a modified version of epoetin alpha, and was originally developed by Amgen in 2001
Executive Summary
Espicom's generics company reports will help you to understand the dynamic and complex issues affecting the business of leading generic industry players. These informative reports provide an insight into the company, covering the structure of the business, the most recent quarterly and annual financial results, information on the company's active product lines and ANDA approvals, along with a review of major developments, such as M&A activity, strategic alliances, and litigation.
Customers who bought this item also bought
Cipla Generics Company Intelligence Report
Dr. Reddy's Laboratories Limited (DRREDDY) - Financial and Strategic SWOT Analysis Review
Dr. Reddy's Laboratories Limited - Product Pipeline Review - Q1 2011
Perrigo Generics Company Intelligence Report
Dr. Reddy's Laboratories Limited - Product Pipeline Review - Q4 2010
Wockhardt Generics Company Intelligence Report
Aspen Pharmacare Generics Company Intelligence Report
Aurobindo Generics Company Intelligence Report
Zydus Cadila Generics Company Intelligence Report
Lupin Generics Company Intelligence Report
|
|
|
|
